
The first approved GA treatment leaves room for additional therapies.

The first approved GA treatment leaves room for additional therapies.

Andrew Pucker, OD, MS, PhD, FAAO, and George Magrath, MD, discuss Lexitas Pharma Services' work on modification of the National Eye Institute's corneal fluorescein staining scale.

Published: October 16th 2023 | Updated: